Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV

Completed · Phase 3

Conditions studied: Cytomegalovirus Infections, HIV Infections

In brief

Cytomegalovirus (CMV) infection is a common opportunistic infection (OI) in HIV patients. The purpose of this study is to find out whether valganciclovir, an antiviral approved by the FDA for the treatment of CMV in the eye, is safe and effective in preventing CMV organ damage in people with HIV.

Key facts

Study ID
NCT00006145
Run by
National Institute of Allergy and Infectious Diseases (NIAID)
People needed
350
Starts
2000-08-01
Expected to finish
2006-02-01
Last updated by the study team
2021-11-01

Who can join

Age: 13 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.